Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Joseph Pilewski, MD
University of Pittsburgh
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
38 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Leuven, Belgium
- Facility name not stated
Montpellier, France
- Facility name not stated
Paris, France
- Facility name not stated
Belfast, United Kingdom
- Facility name not stated
Edinburgh, United Kingdom
- Facility name not stated
Birmingham, Alabama, United States
- Facility name not stated
Palo Alto, California, United States
- Facility name not stated
Denver, Colorado, United States
- Facility name not stated
Hartford, Connecticut, United States
- Facility name not stated
Tampa, Florida, United States
- Facility name not stated
Atlanta, Georgia, United States
- Facility name not stated
Chicago, Illinois, United States
- Facility name not stated
Iowa City, Iowa, United States
- Facility name not stated
Lexington, Kentucky, United States
- Facility name not stated
Baltimore, Maryland, United States
- Facility name not stated
Boston, Massachusetts, United States
- Facility name not stated
Ann Arbor, Michigan, United States
- Facility name not stated
Detroit, Michigan, United States
- Facility name not stated
Grand Rapids, Michigan, United States
- Facility name not stated
Minneapolis, Minnesota, United States
- Facility name not stated
St Louis, Missouri, United States
- Facility name not stated
Omaha, Nebraska, United States
- Facility name not stated
New York, New York, United States
- Facility name not stated
Syracuse, New York, United States
- Facility name not stated
Valhalla, New York, United States
- Facility name not stated
Chapel Hill, North Carolina, United States
- Facility name not stated
Philadelphia, Pennsylvania, United States
- Facility name not stated
Pittsburgh, Pennsylvania, United States
- Facility name not stated
Charleston, South Carolina, United States
- Facility name not stated
Nashville, Tennessee, United States
- Facility name not stated
Dallas, Texas, United States
- Facility name not stated
Fort Worth, Texas, United States
- Facility name not stated
Houston, Texas, United States
- Facility name not stated
Salt Lake City, Utah, United States
- Facility name not stated
Richmond, Virginia, United States
- Facility name not stated
Seattle, Washington, United States
- Facility name not stated
Morgantown, West Virginia, United States
- Facility name not stated
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Feb 2013
- Primary completion
- 30 Apr 2016
- Completion
- 30 Apr 2016
- Last update posted
- 12 May 2017
- Registered enrollment
- 125
- Registry id
- NCT01707290
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.